Innovative lead discovery strategies for tropical diseases

[1]  S. Ōmura,et al.  The life and times of ivermectin — a success story , 2004, Nature Reviews Microbiology.

[2]  A. Anderson.  The process of structure-based drug design. , 2003, Chemistry & biology.

[3]  L. Maes,et al.  Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. , 2006, Journal of ethnopharmacology.

[4]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[5]  R. Ridley.  Research on infectious diseases requires better coordination , 2004, Nature Medicine.

[6]  R. Frank,et al.  New estimates of drug development costs. , 2003, Journal of health economics.

[7]  David Alland,et al.  Targeting Tuberculosis and Malaria through Inhibition of Enoyl Reductase , 2003, Journal of Biological Chemistry.

[8]  J. Bryans,et al.  Academia–industry partnerships in drug discovery , 2006, Expert opinion on drug discovery.

[9]  Katherine A Brown,et al.  Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics. , 2003, Molecular and biochemical parasitology.

[10]  K. Bush,et al.  Taking inventory: antibacterial agents currently at or beyond phase 1. , 2004, Current opinion in microbiology.

[11]  Makedonka Mitreva,et al.  Comparative genomics of nematodes. , 2005, Trends in genetics : TIG.

[12]  Andrew K. Jones,et al.  Model organisms: Chemistry-to-gene screens in Caenorhabditis elegans , 2005, Nature Reviews Drug Discovery.

[13]  Daniel Nilsson,et al.  Comparative Genomics of Trypanosomatid Parasitic Protozoa , 2005, Science.

[14]  Ross L Stein,et al.  High-Throughput Screening in Academia: The Harvard Experience , 2003, Journal of biomolecular screening.

[15]  Pickett,et al.  Computational methods for the prediction of 'drug-likeness' , 2000, Drug discovery today.

[16]  J. McCarter,et al.  RNAi-based discovery and validation of new drug targets in filarial nematodes. , 2005, Trends in parasitology.

[17]  Harren Jhoti,et al.  High-throughput crystallography for lead discovery in drug design , 2002, Nature Reviews Drug Discovery.

[18]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[19]  L. Chitsulo,et al.  Strategic emphases for tropical diseases research: a TDR perspective. , 2002, Trends in microbiology.

[20]  Jaideep P. Sundaram,et al.  Health Innovation Networks to Help Developing Countries Address Neglected Diseases , 2005, Science.

[21]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[22]  Jürgen Bajorath,et al.  Integration of virtual and high-throughput screening , 2002, Nature Reviews Drug Discovery.

[23]  Els Torreele,et al.  Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.

[24]  Christian Scheurer,et al.  Identification of an antimalarial synthetic trioxolane drug development candidate , 2004, Nature.

[25]  Richard T Eastman,et al.  Protein farnesyl transferase inhibitors for the treatment of malaria and African trypanosomiasis. , 2005, Current opinion in investigational drugs.

[26]  Beth Apsel,et al.  Discovery of Trypanocidal Compounds by Whole Cell HTS of Trypanosoma brucei , 2006, Chemical biology & drug design.

[27]  P. Rosenthal,et al.  Antimalarial drug discovery: old and new approaches , 2003, Journal of Experimental Biology.

[28]  J. Barrett,et al.  Antibiotics: where did we go wrong? , 2005, Drug discovery today.

[29]  Mary Moran,et al.  A Breakthrough in R&D for Neglected Diseases: New Ways to Get the Drugs We Need , 2005, PLoS Medicine.

[30]  Li Li,et al.  PlasmoDB: the Plasmodium genome resource. A database integrating experimental and computational data , 2003, Nucleic Acids Res..

[31]  R. Pink,et al.  Opportunities and Challenges in Antiparasitic Drug Discovery , 2005, Nature Reviews Drug Discovery.

[32]  C. R. Bagnell,et al.  Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. , 2004, Acta tropica.

[33]  D. Fairlie,et al.  Anti-malarial effect of histone deacetylation inhibitors and mammalian tumour cytodifferentiating agents. , 2000, International journal for parasitology.

[34]  David A. Fidock,et al.  Antimalarial drug discovery: efficacy models for compound screening , 2004, Nature Reviews Drug Discovery.

[35]  Bindu Gajria,et al.  PlasmoDB: The Plasmodium Genome Resource , 2005 .

[36]  Yongyuth Yuthavong,et al.  Insights into antifolate resistance from malarial DHFR-TS structures , 2003, Nature Structural Biology.

[37]  M. Cotreau,et al.  The Antiparasitic Moxidectin: Safety, Tolerability, and Pharmacokinetics in Humans , 2003, Journal of clinical pharmacology.

[38]  Jonathan E. Allen,et al.  Genome sequence of the human malaria parasite Plasmodium falciparum , 2002, Nature.

[39]  Wim G J Hol,et al.  Drugs to Combat Tropical Protozoan Parasites , 2002, Science.

[40]  P. Rathod,et al.  High-throughput Screening for Potent and Selective Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase* , 2005, Journal of Biological Chemistry.

[41]  J. McKerrow,et al.  A Cysteine Protease Inhibitor Protects Dogs from Cardiac Damage during Infection by Trypanosoma cruzi , 2005, Antimicrobial Agents and Chemotherapy.

[42]  Samiul Hasan,et al.  Prioritizing Genomic Drug Targets in Pathogens: Application to Mycobacterium tuberculosis , 2006, PLoS Comput. Biol..

[43]  Andrej Sali,et al.  Finding Cures for Tropical Diseases: Is Open Source an Answer? , 2004, PLoS medicine.

[44]  Current strategies in the search for novel antiparasitic agents. , 1999, International journal for parasitology.

[45]  J. Guzman,et al.  The New Landscape of Neglected Disease Drug Development , 2005 .

[46]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[47]  S. Nwaka.  Drug discovery and beyond: the role of public-private partnerships in improving access to new malaria medicines. , 2005, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[48]  J. McKerrow.  Designing Drugs for Parasitic Diseases of the Developing World , 2005, PLoS medicine.

[49]  Jon Cohen.  Gates Foundation Picks Winners in Grand Challenges in Global Health , 2005, Science.

[50]  E. Brown.  Screening in Academe: A Perspective on Implementation of University-Based Small Molecule Screening , 2003, Journal of biomolecular screening.

[51]  W. Gutteridge.  TDR collaboration with the pharmaceutical industry. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[52]  F. Cohen,et al.  The Impact of Whole Genome Sequence Data on Drug Discovery—A Malaria Case Study , 2001, Molecular medicine.

[53]  Phillip Gribbon,et al.  High-throughput drug discovery: what can we expect from HTS? , 2005, Drug discovery today.

[54]  Jeffrey D Sachs,et al.  Incorporating a Rapid-Impact Package for Neglected Tropical Diseases with Programs for HIV/AIDS, Tuberculosis, and Malaria , 2006, PLoS medicine.

[55]  Jun O. Liu,et al.  A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.

[56]  Solomon Nwaka,et al.  Science & society: Virtual drug discovery and development for neglected diseases through public–private partnerships , 2003, Nature Reviews Drug Discovery.